VRNI
MCID: VTR013
MIFTS: 61

Vitreoretinopathy, Neovascular Inflammatory (VRNI)

Categories: Eye diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Vitreoretinopathy, Neovascular Inflammatory

MalaCards integrated aliases for Vitreoretinopathy, Neovascular Inflammatory:

Name: Vitreoretinopathy, Neovascular Inflammatory 58 76 30 13 6 41
Proliferative Vitreoretinopathy 58 12 76 15 17 74
Adniv 58 60 76
Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy 60 38
Vrni 58 76
Pvr 58 76
Vitreoretinopathy, Neovascular Inflammatory, Autosomal Dominant; Adniv 58
Vitreoretinopathy, Neovascular Inflammatory, Autosomal Dominant 58
Neovascular Inflammatory Vitreoretinopathy Autosomal Dominant 76
Proliferative Vitreoretinopathy; Pvr 58
Vitreoretinopathy, Proliferative 45
Proliferative Vitreo-Retinopathy 74
Vitreoretinopathy Proliferative 56
Retinitis Proliferans 12

Characteristics:

Orphanet epidemiological data:

60
autosomal dominant neovascular inflammatory vitreoretinopathy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: All ages;

OMIM:

58
Inheritance:
autosomal dominant (11q13)


HPO:

33
vitreoretinopathy, neovascular inflammatory:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 60  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:9719
OMIM 58 193235
KEGG 38 H01798
MeSH 45 D018630
ICD10 via Orphanet 35 H35.2
Orphanet 60 ORPHA329211

Summaries for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot : 76 Vitreoretinopathy, neovascular inflammatory: An autoimmune condition of the eye that sequentially mimics uveitis, retinitis pigmentosa, and proliferative diabetic retinopathy as it progresses to complete blindness. Patients present during the second or third decade of life with posterior uveitis and reduction of the electroretinogram b-wave. They become more symptomatic when cataracts, cystoid macular edema, and disk edema diminish visual acuity during the second stage. Severe vision loss begins during the third stage when proliferative retinal neovascularization and epiretinal membranes appear. There is an ongoing pigmentary retinal degeneration and peripheral visual field loss during all stages. In the fourth stage, proliferative vitreoretinopathy causes tractional retinal detachments at the macula and vitreous base. The fifth or end-stage disease is marked by phthisis.

MalaCards based summary : Vitreoretinopathy, Neovascular Inflammatory, also known as proliferative vitreoretinopathy, is related to uveitis and macular holes. An important gene associated with Vitreoretinopathy, Neovascular Inflammatory is CAPN5 (Calpain 5), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Triamcinolone and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are blindness and abnormal electroretinogram

OMIM : 58 Autosomal dominant neovascular inflammatory vitreoretinopathy is a blinding disorder that shares some clinical features with retinitis pigmentosa (see 268000), uveitis, and proliferative diabetic retinopathy (see 603933). Features include prominent ocular inflammation; vascular dropout, large spots of hyperpigmentation, and neovascularization of the peripheral and posterior retina; vitreous hemorrhage; and retinal detachment (summary by Sheffield et al., 1992). (193235)

Related Diseases for Vitreoretinopathy, Neovascular Inflammatory

Diseases related to Vitreoretinopathy, Neovascular Inflammatory via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Related Disease Score Top Affiliating Genes
1 uveitis 30.3 CAPN5 CCL2 TGFB2
2 macular holes 30.3 ADM CCL2 TGFB2
3 macular retinal edema 30.0 CAPN5 CCL2
4 microvascular complications of diabetes 1 29.4 CCL2 FGF2 GFAP HGF TGFB2 TIMP1
5 poliomyelitis 11.3
6 paralytic poliomyelitis 11.2
7 cleft palate, isolated 11.2
8 cleft lip/palate-ectodermal dysplasia syndrome 11.2
9 female stress incontinence 11.2
10 agraphia 11.2
11 enterocele 11.2
12 prolapse of female genital organ 11.2
13 basilar artery insufficiency 11.2
14 ovarian cystic teratoma 11.2
15 mature teratoma of the ovary 11.2
16 urethral diverticulum 11.2
17 microvascular complications of diabetes 5 10.7
18 microvascular complications of diabetes 2 10.6
19 retinal detachment 10.4
20 preretinal fibrosis 10.3 GFAP TGFB2
21 retinitis 10.3
22 breast cancer 10.3
23 cornea cancer 10.3 FGF2 GFAP
24 stiff skin syndrome 10.3 TGFB1 TGFB2
25 cataract 10.2
26 laryngitis 10.2 FGF2 TGFB1
27 tuberculoid leprosy 10.2 TGFB1 TGFB2
28 diabetic foot ulcers 10.2 CCL2 TGFB1
29 chronic myocardial ischemia 10.2 FGF2 HGF
30 pigmentary disorder, reticulate, with systemic manifestations, x-linked 10.2
31 human immunodeficiency virus type 1 10.2
32 coats disease 10.1
33 neuroma 10.1 FGF2 GFAP TGFB1
34 peyronie's disease 10.1 CCL2 TGFB1 TGFB2
35 telangiectasis 10.1
36 tuberous sclerosis 10.1
37 eales disease 10.1
38 ascending cholangitis 10.0 CCL2 TGFB1
39 nonspecific interstitial pneumonia 10.0 CCL2 FGF2 TGFB1
40 hydrocephalus 10.0 GFAP TGFB1 TGFB2
41 tetralogy of fallot 10.0
42 orofacial cleft 3 10.0
43 peripheral vascular disease 10.0
44 thrombosis 10.0
45 portal vein thrombosis 10.0
46 cleft lip 10.0
47 cleft lip/palate 10.0
48 macular dystrophy, dominant cystoid 10.0
49 retinoblastoma 10.0
50 von hippel-lindau syndrome 10.0

Graphical network of the top 20 diseases related to Vitreoretinopathy, Neovascular Inflammatory:



Diseases related to Vitreoretinopathy, Neovascular Inflammatory

Symptoms & Phenotypes for Vitreoretinopathy, Neovascular Inflammatory

Human phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

33 (show all 9)
# Description HPO Frequency HPO Source Accession
1 blindness 33 HP:0000618
2 abnormal electroretinogram 33 HP:0000512
3 retinal detachment 33 HP:0000541
4 uveitis 33 HP:0000554
5 vitreoretinopathy 33 HP:0007773
6 vitreous hemorrhage 33 HP:0007902
7 large hyperpigmented retinal spots 33 HP:0007658
8 posterior retinal neovascularization 33 HP:0007778
9 peripheral retinal neovascularization 33 HP:0030667

Symptoms via clinical synopsis from OMIM:

58
Eyes:
blindness
retinal detachment
vitreous hemorrhage
neovascular inflammatory vitreoretinopathy
prominent ocular inflammation
more
Lab:
distinct b-wave abnormality on electrooculography

Clinical features from OMIM:

193235

GenomeRNAi Phenotypes related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

27 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.47 TGFB2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.47 TGFB2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.47 CAPN5
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.47 TGFB2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.47 CAPN5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.47 TGFB2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.47 TGFB2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.47 CAPN5 TGFB1 TGFB2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.47 TGFB2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.47 TGFB1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.47 CAPN5
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.47 CAPN5

MGI Mouse Phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 ADM FGF1 FGF2 FN1 HGF SPARC
2 cardiovascular system MP:0005385 9.92 ADM FGF2 FN1 GFAP HGF TGFB1
3 homeostasis/metabolism MP:0005376 9.85 ADM FGF1 FGF2 FN1 GFAP SPARC
4 immune system MP:0005387 9.61 ADM CAPN5 CCL2 FN1 GFAP SPARC
5 muscle MP:0005369 9.1 ADM FGF2 FN1 GFAP TGFB1 TGFB2

Drugs & Therapeutics for Vitreoretinopathy, Neovascular Inflammatory

Drugs for Vitreoretinopathy, Neovascular Inflammatory (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
2
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
3
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
4 Hormones Phase 4,Phase 3,Early Phase 1
5 Triamcinolone hexacetonide Phase 4,Phase 3
6 Anti-Inflammatory Agents Phase 4,Phase 3
7 glucocorticoids Phase 4,Phase 3,Early Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Early Phase 1
9 Triamcinolone diacetate Phase 4,Phase 3
10 triamcinolone acetonide Phase 4,Phase 3
11 Hormone Antagonists Phase 4,Phase 3,Early Phase 1
12 Peripheral Nervous System Agents Phase 4,Phase 3
13 Dermatologic Agents Phase 4
14 Anesthetics Phase 4
15 Immunosuppressive Agents Phase 4,Phase 3
16 Anesthetics, Local Phase 4
17 Immunologic Factors Phase 4,Phase 3
18 Central Nervous System Depressants Phase 4,Not Applicable
19
Colchicine Approved Phase 3 64-86-8 2833 6167
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
21
Fluorouracil Approved Phase 3 51-21-8 3385
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
23
Dalteparin Approved Phase 3 9005-49-6
24
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
25
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
26
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 54670067 5785
27 Antimitotic Agents Phase 3
28 Antirheumatic Agents Phase 3
29 Anticoagulants Phase 3
30 Fibrinolytic Agents Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 Antiemetics Phase 3
33 calcium heparin Phase 3
34 Gastrointestinal Agents Phase 3
35
protease inhibitors Phase 3
36 HIV Protease Inhibitors Phase 3
37 Calcium, Dietary Phase 3
38 BB 1101 Phase 3
39 Autonomic Agents Phase 3
40 Heparin, Low-Molecular-Weight Phase 3
41 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
42 Antimetabolites Phase 3
43 Antimetabolites, Antineoplastic Phase 3
44
Bevacizumab Approved, Investigational Phase 2,Not Applicable 216974-75-3
45 Angiogenesis Inhibitors Phase 2,Not Applicable
46 Antineoplastic Agents, Immunological Phase 2,Not Applicable
47 Angiogenesis Modulating Agents Phase 2,Not Applicable
48
Temazepam Approved, Investigational Not Applicable 846-50-4 5391
49
Racepinephrine Approved Early Phase 1 329-65-7 838
50
Epinephrine Approved, Vet_approved Early Phase 1 51-43-4 5816

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Isotretinoin for Proliferative Vitreoretinopathy Completed NCT01445028 Phase 4 Isotretinoin
2 Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
3 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
4 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
5 The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR Unknown status NCT00371020 Phase 3 low molecular weight heparin, 5-FU
6 Comparison High-Density Silicone Oils in Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
7 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
8 Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Completed NCT00373282 Phase 3 Triamcinolone acetonide
9 The Silicone Study Completed NCT00000140 Phase 3 Perfluoropropane;Sulfur Hexafluoride;Silicone Oil
10 Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Recruiting NCT02834559 Phase 3 5-fluorouracil and low molecular weight heparin;Placebo
11 Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study Recruiting NCT02873026 Phase 3 Triamcinolone Acetonide
12 Dacorin for Proliferative Vitreoretinopathy Completed NCT02865031 Phase 1, Phase 2 Decorin
13 Stem Cell Therapy for Outer Retinal Degenerations Recruiting NCT02903576 Phase 1, Phase 2
14 Bevacizumab Against Recurrent Retinal Detachment Active, not recruiting NCT02192970 Phase 2 Bevacizumab
15 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery. Unknown status NCT01959568 Not Applicable
16 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel Unknown status NCT00892619 Not Applicable
17 Optical Coherence Tomography - Rescan During Dissection of Macular Membranes Unknown status NCT02748421 Not Applicable
18 Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT03208205
19 Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments Completed NCT01255293 Not Applicable
20 Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. Completed NCT01860586 Not Applicable Bevacizumab
21 Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment Completed NCT03542162 Not Applicable
22 23 Gauge and 20 Gauge Vitrectomy for Rhegmatogenous Retinal Detachments Completed NCT01716507 Not Applicable
23 Adaptive Optics in PVR Recruiting NCT03551574
24 Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) Not yet recruiting NCT03727776 Early Phase 1 Adrenocorticotropic Hormone
25 Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria Not yet recruiting NCT02871531 Not Applicable

Search NIH Clinical Center for Vitreoretinopathy, Neovascular Inflammatory

Cochrane evidence based reviews: vitreoretinopathy, proliferative

Genetic Tests for Vitreoretinopathy, Neovascular Inflammatory

Genetic tests related to Vitreoretinopathy, Neovascular Inflammatory:

# Genetic test Affiliating Genes
1 Vitreoretinopathy, Neovascular Inflammatory 30 CAPN5

Anatomical Context for Vitreoretinopathy, Neovascular Inflammatory

MalaCards organs/tissues related to Vitreoretinopathy, Neovascular Inflammatory:

42
Eye, Retina, Endothelial, Monocytes, Placenta, Skin, Ovary

Publications for Vitreoretinopathy, Neovascular Inflammatory

Articles related to Vitreoretinopathy, Neovascular Inflammatory:

(show top 50) (show all 702)
# Title Authors Year
1
Outcomes of 25-gauge vitrectomy with relaxing retinectomy for retinal detachment secondary to proliferative vitreoretinopathy. ( 30972375 )
2019
2
Correlation of transforming growth factor β-1 vitreous levels with clinical severity of proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. ( 30309666 )
2019
3
SINGLE NUCLEOTIDE POLYMORPHISMS IN RETINAL DETACHMENT PATIENTS WITH AND WITHOUT PROLIFERATIVE VITREORETINOPATHY. ( 30807515 )
2019
4
P38 inhibition reverses TGFβ1 and TNFα-induced contraction in a model of proliferative vitreoretinopathy. ( 31069271 )
2019
5
Intraocular application of Mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries. ( 30918327 )
2019
6
Proteomic evidence that ABCA4 is vital for traumatic proliferative vitreoretinopathy formation and development. ( 30738069 )
2019
7
Proliferative Vitreoretinopathy: A Review. ( 30585928 )
2019
8
Safety, pharmacokinetics, and prevention effect of intraocular crocetin in proliferative vitreoretinopathy. ( 30551371 )
2019
9
BMP7 antagonizes proliferative vitreoretinopathy through retinal pigment epithelial fibrosis in vivo and in vitro. ( 30383450 )
2019
10
Comparison of Surgically Excised Premacular Membranes in Eyes with Macular Pucker and Proliferative Vitreoretinopathy. ( 30373411 )
2019
11
Anterior proliferative vitreoretinopathy in a patient with Coats disease. ( 29487831 )
2018
12
Outcomes of Retinectomy in Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy. ( 30369377 )
2018
13
Internal Limiting Membrane Peeling in Macula-off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy. ( 29621507 )
2018
14
PREDICTIVE FACTORS FOR PROLIFERATIVE VITREORETINOPATHY FORMATION AFTER UNCOMPLICATED PRIMARY RETINAL DETACHMENT REPAIR. ( 29787465 )
2018
15
Clinicopathologic Correlation of a Subretinal Proliferative Vitreoretinopathy Band in a Patient with Chronic Recurrent Retinal Detachment. ( 29928223 )
2018
16
Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial. ( 30012187 )
2018
17
Internal Limiting Membrane Peeling in Macula-Off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy. ( 30190076 )
2018
18
Internal Limiting Membrane Peeling in Macula-off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy. ( 30274783 )
2018
19
SUBRETINAL TRANSPLANTATION OF AN AUTOLOGOUS RETINAL FREE FLAP FOR CHRONIC RETINAL DETACHMENT WITH PROLIFERATIVE VITREORETINOPATHY WITH AND WITHOUT MACULAR HOLE. ( 29293208 )
2018
20
NOVEL ENDOSCOPE-ASSISTED VITREOUS SURGERY COMBINED WITH ATMOSPHERIC ENDOSCOPIC TECHNIQUE AND/OR SUBRETINAL ENDOSCOPIC TECHNIQUE FOR RHEGMATOGENOUS RETINAL DETACHMENT WITH GRADE C PROLIFERATIVE VITREORETINOPATHY. ( 29528982 )
2018
21
Levels of Anti-Retinal Antibodies in Retinal Detachment and Proliferative Vitreoretinopathy. ( 29547015 )
2018
22
EFFICACY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN VITRECTOMY FOR PATIENTS WITH PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT: A Meta-analysis of Prospective Studies. ( 28272285 )
2018
23
ASSOCIATION STUDY BETWEEN POLYMORPHISMS OF THE p53 AND LYMPHOTOXIN ALPHA (LTA) GENES AND THE RISK OF PROLIFERATIVE VITREORETINOPATHY/RETINAL DETACHMENT IN A MEXICAN POPULATION. ( 28106707 )
2018
24
Prophylactic chorioretinectomy for eye injuries with high proliferative-vitreoretinopathy risk. ( 28635048 )
2018
25
Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one. ( 28639085 )
2018
26
Effect of Biodegradable Scleral Plugs Containing Curcumin on Proliferative Vitreoretinopathy. ( 28942445 )
2018
27
Postoperative aqueous humour flare as a surrogate marker for proliferative vitreoretinopathy development. ( 29068530 )
2018
28
Evaluation of the Effect of Everolimus on Retinal Pigment Epithelial Cells and Experimental Proliferative Vitreoretinopathy. ( 29182404 )
2018
29
OUTCOMES OF REPEAT PARS PLANA VITRECTOMY AFTER FAILED SURGERY FOR PROLIFERATIVE VITREORETINOPATHY. ( 29232332 )
2018
30
Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target. ( 29246578 )
2018
31
Twenty five-gauge endoscopic vitrectomy for proliferative vitreoretinopathy with severe corneal opacity. ( 29460017 )
2018
32
Comprehensive circular RNA profiling of proliferative vitreoretinopathy and its clinical significance. ( 30597308 )
2018
33
Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial. ( 30381390 )
2018
34
Altered Decorin Biology in Proliferative Vitreoretinopathy: A Mechanistic and Cohort Study. ( 30347087 )
2018
35
Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study. ( 30128605 )
2018
36
Effects of Curcumin on Epidermal Growth Factor in Proliferative Vitreoretinopathy. ( 29975931 )
2018
37
Experimental proliferative vitreoretinopathy in rabbits by delivery of bioactive proteins with gelatin microspheres. ( 29906511 )
2018
38
Comparison of SNP Genotypes Related to Proliferative Vitreoretinopathy (PVR) across Slovenian and European Subpopulations. ( 29862067 )
2018
39
Animal Models of Proliferative Vitreoretinopathy and Their Use in Pharmaceutical Investigations. ( 29723860 )
2018
40
Protective Effects of Fucoidan on Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells and Progression of Proliferative Vitreoretinopathy. ( 29698960 )
2018
41
New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies. ( 29461171 )
2018
42
Single-Port Vitrectomy and "Oleodelamination" for the Management of Retinal Detachment Complicated by Proliferative Vitreoretinopathy. ( 28541958 )
2017
43
Outcomes of Vitrectomy in Pediatric Retinal Detachment with Proliferative Vitreoretinopathy. ( 28840039 )
2017
44
Validity of aqueous flare measurement in predicting proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. ( 27682827 )
2017
45
SMOKING IS A RISK FACTOR FOR PROLIFERATIVE VITREORETINOPATHY AFTER TRAUMATIC RETINAL DETACHMENT. ( 27787448 )
2017
46
CHOROIDAL THICKNESS CHANGES AFTER VITRECTOMY WITH SILICONE OIL TAMPONADE FOR PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT. ( 28033232 )
2017
47
Preoperative aqueous humour flare values do not predict proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. ( 28077370 )
2017
48
A Surgical Technique for the Management of Retinal Detachment Associated With Severe Proliferative Vitreoretinopathy. ( 28125442 )
2017
49
Proliferative Vitreoretinopathy in Treated Retinoblastoma. ( 28435935 )
2017
50
Epiretinal membrane and cystoid macular edema as predictive factors of recurrent proliferative vitreoretinopathy. ( 29066859 )
2017

Variations for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

76
# Symbol AA change Variation ID SNP ID
1 CAPN5 p.Arg243Leu VAR_069277 rs397514601
2 CAPN5 p.Leu244Pro VAR_069278 rs397514602

ClinVar genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CAPN5 NM_004055.4(CAPN5): c.728G> T (p.Arg243Leu) single nucleotide variant Pathogenic rs397514601 GRCh37 Chromosome 11, 76826469: 76826469
2 CAPN5 NM_004055.4(CAPN5): c.728G> T (p.Arg243Leu) single nucleotide variant Pathogenic rs397514601 GRCh38 Chromosome 11, 77115423: 77115423
3 CAPN5 NM_004055.4(CAPN5): c.731T> C (p.Leu244Pro) single nucleotide variant Pathogenic rs397514602 GRCh37 Chromosome 11, 76826472: 76826472
4 CAPN5 NM_004055.4(CAPN5): c.731T> C (p.Leu244Pro) single nucleotide variant Pathogenic rs397514602 GRCh38 Chromosome 11, 77115426: 77115426
5 CAPN5 NM_004055.4(CAPN5): c.865C> T (p.Arg289Trp) single nucleotide variant Pathogenic rs886041303 GRCh38 Chromosome 11, 77115560: 77115560
6 CAPN5 NM_004055.4(CAPN5): c.865C> T (p.Arg289Trp) single nucleotide variant Pathogenic rs886041303 GRCh37 Chromosome 11, 76826606: 76826606
7 CAPN5 NM_004055.4(CAPN5): c.1894C> A (p.Leu632Ile) single nucleotide variant Likely benign rs111264315 GRCh37 Chromosome 11, 76834887: 76834887
8 CAPN5 NM_004055.4(CAPN5): c.1894C> A (p.Leu632Ile) single nucleotide variant Likely benign rs111264315 GRCh38 Chromosome 11, 77123841: 77123841

Expression for Vitreoretinopathy, Neovascular Inflammatory

Search GEO for disease gene expression data for Vitreoretinopathy, Neovascular Inflammatory.

Pathways for Vitreoretinopathy, Neovascular Inflammatory

Pathways related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 CAPN5 CCL2 FGF1 FGF2 FN1 GFAP
2
Show member pathways
13.45 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
3
Show member pathways
13.33 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
4
Show member pathways
13.31 CAPN5 CCL2 FN1 TGFB1 TGFB2 VTN
5
Show member pathways
13.28 CCL2 FGF1 FGF2 FN1 HGF TGFB1
6
Show member pathways
13.24 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
7
Show member pathways
13.23 FN1 HGF SPARC TGFB1 TGFB2 TIMP1
8
Show member pathways
13.23 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
9
Show member pathways
13.19 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
10
Show member pathways
13 FGF1 FGF2 FN1 HGF TGFB1 TGFB2
11
Show member pathways
12.98 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
12
Show member pathways
12.91 FGF1 FGF2 FN1 HGF VTN
13 12.79 FGF1 FGF2 FN1 HGF TGFB1 TGFB2
14 12.7 FGF1 FGF2 HGF TGFB1 TGFB2
15
Show member pathways
12.7 FGF1 FGF2 HGF TGFB1 TGFB2
16
Show member pathways
12.64 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
17
Show member pathways
12.58 CAPN5 FGF2 FN1 SPARC TGFB1 TGFB2
18
Show member pathways
12.52 CCL2 FGF2 FN1 TIMP1
19
Show member pathways
12.35 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
20
Show member pathways
12.2 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
21 12.18 FGF2 FN1 HGF TGFB1 TGFB2 VTN
22 12.07 FGF1 TGFB1 TGFB2
23 12.04 HGF TGFB1 TGFB2
24 11.99 FGF2 HGF TGFB1
25 11.94 CCL2 GFAP TGFB1
26 11.93 FN1 SPARC TGFB1 VTN
27
Show member pathways
11.93 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
28 11.89 CCL2 FN1 TGFB1 TGFB2
29 11.83 FN1 TGFB1 TGFB2
30 11.8 CCL2 TGFB1 TGFB2
31 11.79 CCL2 FGF2 FN1 HGF TGFB1 TIMP1
32
Show member pathways
11.69 TGFB1 TGFB2 VTN
33 11.68 CCL2 TGFB1 TGFB2
34 11.64 FGF2 TGFB1 TGFB2
35 11.62 FN1 SPARC TIMP1 VTN
36 11.6 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
37 11.58 SPARC TGFB1 TGFB2 VTN
38 11.49 FGF2 FN1 TGFB1 TGFB2
39 11.47 FGF2 FN1 VTN
40 11.47 CCL2 HGF TGFB1 TGFB2
41 11.44 FGF1 FGF2 HGF TGFB1
42 11.26 HGF TGFB1 TGFB2
43 11.23 CCL2 FGF1 FGF2 HGF TGFB1 TIMP1
44 11.12 FGF2 TGFB1
45 11.12 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
46 11.11 CCL2 TIMP1
47 11.02 FN1 TGFB1
48 10.97 CCL2 TIMP1
49 10.95 FN1 TGFB1
50 10.92 HGF TGFB1

GO Terms for Vitreoretinopathy, Neovascular Inflammatory

Cellular components related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 ADM CCL2 FGF1 FGF2 FN1 HGF
2 collagen-containing extracellular matrix GO:0062023 9.77 FN1 SPARC TGFB1 TGFB2 VTN
3 extracellular matrix GO:0031012 9.73 FGF1 FN1 SPARC TGFB1 TIMP1 VTN
4 extracellular space GO:0005615 9.7 ADM CCL2 FGF1 FGF2 FN1 HGF
5 basement membrane GO:0005604 9.62 FN1 SPARC TIMP1 VTN
6 blood microparticle GO:0072562 9.58 FN1 TGFB1 VTN
7 platelet alpha granule lumen GO:0031093 9.1 FN1 HGF SPARC TGFB1 TGFB2 TIMP1

Biological processes related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.91 ADM SPARC TGFB1 TGFB2
2 positive regulation of cell proliferation GO:0008284 9.91 ADM FGF1 FGF2 FN1 TGFB1 TGFB2
3 angiogenesis GO:0001525 9.88 CCL2 FGF1 FGF2 FN1 TGFB2
4 positive regulation of protein kinase B signaling GO:0051897 9.85 FGF1 FGF2 HGF TGFB1
5 MAPK cascade GO:0000165 9.85 CCL2 FGF1 FGF2 HGF TGFB1
6 response to hypoxia GO:0001666 9.84 ADM TGFB1 TGFB2
7 cell proliferation GO:0008283 9.84 FGF1 TGFB1 TGFB2 VTN
8 activation of MAPK activity GO:0000187 9.83 FGF1 FGF2 HGF
9 extracellular matrix organization GO:0030198 9.83 FGF2 FN1 GFAP SPARC VTN
10 response to organic substance GO:0010033 9.81 ADM TGFB1 TIMP1
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 HGF TGFB1 VTN
12 positive regulation of angiogenesis GO:0045766 9.8 ADM FGF1 FGF2 HGF
13 cytokine-mediated signaling pathway GO:0019221 9.8 CCL2 FGF2 FN1 HGF TGFB1 TIMP1
14 neural tube closure GO:0001843 9.79 ADM TGFB1 TGFB2
15 positive regulation of MAP kinase activity GO:0043406 9.77 FGF1 FGF2 TGFB1
16 inner ear development GO:0048839 9.74 SPARC TGFB1 TGFB2
17 animal organ regeneration GO:0031100 9.73 ADM HGF TGFB1
18 positive regulation of cell division GO:0051781 9.71 FGF1 FGF2 TGFB1 TGFB2
19 epithelial to mesenchymal transition GO:0001837 9.69 HGF TGFB1 TGFB2
20 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.67 TGFB1 TGFB2
21 positive regulation of sprouting angiogenesis GO:1903672 9.67 FGF1 FGF2
22 cell-cell junction organization GO:0045216 9.66 TGFB1 TGFB2
23 hyaluronan catabolic process GO:0030214 9.65 FGF2 TGFB1
24 positive regulation of DNA biosynthetic process GO:2000573 9.65 FGF2 HGF
25 negative regulation of immune response GO:0050777 9.65 TGFB1 TGFB2
26 response to wounding GO:0009611 9.65 ADM FN1 GFAP TGFB1 TGFB2
27 pathway-restricted SMAD protein phosphorylation GO:0060389 9.64 TGFB1 TGFB2
28 cell activation GO:0001775 9.64 TGFB1 TIMP1
29 platelet degranulation GO:0002576 9.63 FN1 HGF SPARC TGFB1 TGFB2 TIMP1
30 salivary gland morphogenesis GO:0007435 9.62 TGFB1 TGFB2
31 heart valve morphogenesis GO:0003179 9.61 TGFB1 TGFB2
32 connective tissue replacement involved in inflammatory response wound healing GO:0002248 9.59 TGFB1 TIMP1
33 negative regulation of macrophage cytokine production GO:0010936 9.58 TGFB1 TGFB2
34 neuron projection regeneration GO:0031102 9.58 ADM GFAP
35 regulation of signaling receptor activity GO:0010469 9.56 ADM CCL2 FGF1 FGF2 HGF TGFB1
36 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.52 FGF1 FGF2
37 wound healing GO:0042060 9.1 FGF2 FN1 SPARC TGFB1 TGFB2 TIMP1

Molecular functions related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.73 ADM CCL2 FN1 TGFB2
2 heparin binding GO:0008201 9.62 FGF1 FGF2 FN1 VTN
3 cytokine activity GO:0005125 9.55 CCL2 FGF2 TGFB1 TGFB2 TIMP1
4 collagen binding GO:0005518 9.54 FN1 SPARC VTN
5 fibroblast growth factor receptor binding GO:0005104 9.46 FGF1 FGF2
6 type II transforming growth factor beta receptor binding GO:0005114 9.4 TGFB1 TGFB2
7 type III transforming growth factor beta receptor binding GO:0034714 9.26 TGFB1 TGFB2
8 integrin binding GO:0005178 9.26 FGF1 FGF2 FN1 VTN
9 growth factor activity GO:0008083 9.1 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1

Sources for Vitreoretinopathy, Neovascular Inflammatory

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....